Since it has been demonstrated that HIF-1α is overexpressed in a number of different forms of cancer, including CRC, the inhibition of HIF-1α is currently at the forefront of the list of targets for anti-tumor therapy [252]. This evidence concerns the gene HIF1A and neoplasm.